Access Vascular has filed a notice of an exempt offering of securities to raise $22,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Access Vascular is raising $22,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, James Biggins played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Access Vascular
Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Taking a foundationally different approach to thrombus reduction, the company manufactures intravenous catheters from a hydrophilic material which retains significant amounts of water. Engineered to mimic the bodys natural chemistry, Access Vascular catheters are designed to evade the foreign body response and complications that come with it. Our cleared products are HydroPICCand HydroMID.
To learn more about Access Vascular, visit http://www.accessvascularinc.com/
Contact:
James Biggins, Chief Executive Officer
781-538-6594
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.